What is SEER's current stock price?

SEER (Seer, Inc.) is currently trading at $1.79 with a market cap of $98.4M.

What sector is Seer, Inc. in?

Seer, Inc. (SEER) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is SEER a good stock to buy?

Analysts have a Buy consensus on SEER with a price target of $4.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

SEER Seer, Inc.

Healthcare

$1.79+1.13%ClosedMarket Cap: $98.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.42

P/S

6.54

EV/EBITDA

-1.08

DCF Value

$-10.67

FCF Yield

-50.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

48.3%

Operating Margin

-496.4%

Net Margin

-468.7%

ROE

-26.6%

ROA

-25.9%

ROIC

-28.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$2.8M	$-16.8M	$—
Q4 null	$4.1M	$-16.0M	$—
FY null	$16.1M	$-73.6M	$—
Q3 null	$4.1M	$-18.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$4.00

Target (Median)

$4.00

Target Range

$4.00 - $4.00

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Horn David R.officer: PRESIDENT & CFO

SellThu May 21

Bazarko Anthony R.officer: Chief Commercial Officer

SellMon May 11

Bazarko Anthony R.officer: Chief Commercial Officer

SellMon May 11

Bazarko Anthony R.

SellMon May 11

Horn David R.officer: PRESIDENT & CFO

SellThu Feb 19

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.64

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Peers

QSI